Elicio Therapeutics (ELTX) news
Recent news
Elicio Therapeutics Inc: B. Riley cuts target price to $8 from $27
B. Riley Securities has revised its price target for Elicio Therapeutics (NASDAQ: ELTX) from $27 to $8, marking a significant downward adjustment in its forecast for the stock. The firm initially initiated a "Buy" rating for Elicio in June 2026 with a $27 price target, which represented a projected…
AInvest Wire · Sep 24, 2026Elicio Therapeutics announces closing of $15 million registered direct offering
Elicio Therapeutics, Inc. (Nasdaq: ELTX) has completed a registered direct offering, raising $15 million in gross proceeds, according to the company’s recent announcement. The offering included the sale of 1,261,830 shares of common stock and accompanying warrants to purchase an equivalent number…
AInvest Wire · Jul 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.